Skip to main content

6 Result(s)

within Chetan Lathia Remove this filter

and

  1. Article

    Open Access

    Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

    Regorafenib, a multi-kinase inhibitor, is used in the treatment of patients with metastatic colorectal cancer refractory to standard therapy. However, this benefit was limited to 1.4 months improvement in over...

    Andrea Li Ann Wong, Joline Si **g Lim, Arvind Sinha… in Journal of Translational Medicine (2015)

    Download PDF (2200 KB) View Article

  2. No Access

    Article

    Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study

    In vitro data indicate that the sorafenib is a moderate inhibitor of cytochrome P450 (CYP) enzymes, including CYP3A4, CYP2C19, and CYP2D6. This phase I/II study in patients with advanced melanoma evaluated the...

    Keith T. Flaherty, Chetan Lathia, Reginald F. Frye… in Cancer Chemotherapy and Pharmacology (2011)

  3. Article

    Open Access

    Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors

    Sorafenib, a multikinase inhibitor of Raf and several growth factor receptors, is under investigation in combination with dacarbazine, a commonly used chemotherapeutic agent for the treatment of many cancers. ...

    Erich Brendel, Matthias Ludwig, Chetan Lathia… in Cancer Chemotherapy and Pharmacology (2011)

    Download PDF (367 KB) View Article

  4. No Access

    Article

    Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

    Sorafenib is a novel, small-molecule anticancer compound that inhibits tumor cell proliferation by targeting Raf in the Raf/MEK/ERK signalling pathway, and inhibits angiogenesis by targeting tyrosine kinases s...

    Chetan Lathia, John Lettieri, Frank Cihon… in Cancer Chemotherapy and Pharmacology (2006)

  5. No Access

    Article

    Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies

    Bay 38-3441 is a camptothecin glycoconjugate which stabilizes the active lactone form of camptothecin and allows selective uptake into tumor cells. We conducted a phase I study of Bay 38-3441 administered as a...

    Eric X. Chen, Gerald Batist, Lillian L. Siu, Naeema Bangash… in Investigational New Drugs (2005)

  6. No Access

    Article

    Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment

    Abstract

    Chetan Lathia, Gini F. Fleming, Mark Meyer… in Cancer Chemotherapy and Pharmacology (2002)